David Ian Bell
Director/Board Member en BIOTEST AG .
Fortuna: 180 101 $ al 31/03/2024
Cargos activos de David Ian Bell
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
GRIFOLS, S.A. | General Counsel | 01/07/2003 | - |
Corporate Officer/Principal | 01/01/2016 | - | |
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. | Director/Board Member | 20/05/2020 | - |
BIOTEST AG | Director/Board Member | 01/06/2022 | - |
Grifols USA, Inc.
Grifols USA, Inc. Medical SpecialtiesHealth Technology Grifols USA, Inc. sales and markets automated analyzers and dosing machines. The company supplies plasma products, diagnostic reagents, analyzers and dosing machines. Grifols USA was founded in 1948 and is headquartered in Los Angeles, CA. | General Counsel | 01/07/2003 | - |
Director/Board Member | 07/06/2011 | 28/05/2013 | |
Corporate Officer/Principal | 28/05/2013 | 30/08/2013 | |
Singulex, Inc.
Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Director/Board Member | - | - |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The private company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Director/Board Member | - | - |
BPC Plasma, Inc.
BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Director/Board Member | - | - |
Alkahest, Inc.
Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Director/Board Member | - | - |
GigaGen, Inc.
GigaGen, Inc. BiotechnologyHealth Technology GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA. | Director/Board Member | - | - |
░░░░░░░ ░░░░░░░░░░ ░ ░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ | - | - | |
░░░░░░ ░░░░ ░░░░ | ░░░░░░░░ | - | - |
░░░░░░░ ░░░░░░░ | - | - | |
░░░░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Historial de carrera de David Ian Bell
Antiguos cargos conocidos de David Ian Bell.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░ ░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formación de David Ian Bell.
University of California, Irvine | Undergraduate Degree |
Southwestern Law School | Graduate Degree |
Harvard Law School | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 16 |
España | 3 |
Alemania | 2 |
Operativa
Director/Board Member | 10 |
General Counsel | 4 |
Corporate Officer/Principal | 4 |
Sectorial
Health Technology | 12 |
Commercial Services | 5 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
GRIFOLS, S.A. | Health Technology |
BIOTEST AG | Health Technology |
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. | Health Technology |
Empresas privadas | 14 |
---|---|
Aradigm Corp.
Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Singulex, Inc.
Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Commercial Services |
Grifols, Inc.
Grifols, Inc. Pharmaceuticals: MajorHealth Technology Grifols, Inc. manufactures pharmaceuticals. The company is headquartered in Los Angeles, CA. | Health Technology |
Alkahest, Inc.
Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Health Technology |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The private company is based in Los Angeles, CA. | Health Technology |
Plasma Protein Therapeutics Association
Plasma Protein Therapeutics Association Miscellaneous Commercial ServicesCommercial Services The Plasma Protein Therapeutics Association is a non-profit organization that represents manufacturers and plasma collection centers. The private company is based in Washington and has subsidiaries in the United States. Anita Brikman has been the CEO of the American company since 2023. | Commercial Services |
Grifols USA, Inc.
Grifols USA, Inc. Medical SpecialtiesHealth Technology Grifols USA, Inc. sales and markets automated analyzers and dosing machines. The company supplies plasma products, diagnostic reagents, analyzers and dosing machines. Grifols USA was founded in 1948 and is headquartered in Los Angeles, CA. | Health Technology |
California State Bar Association | |
BPC Plasma, Inc.
BPC Plasma, Inc. Pharmaceuticals: MajorHealth Technology BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL. | Health Technology |
Biomat USA, Inc.
Biomat USA, Inc. Medical/Nursing ServicesHealth Services Biomat USA, Inc. provides plasma derived blood products. The company is headquartered in Los Angeles, CA. | Health Services |
Knapp, Petersen & Clarke PC
Knapp, Petersen & Clarke PC Miscellaneous Commercial ServicesCommercial Services Knapp, Petersen & Clarke PC is a law firm that offers a variety of legal services. The private company is based in Glendale, CA. The firm emphasizes its creativity and accessibility in providing these services. | Commercial Services |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The private company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
GigaGen, Inc.
GigaGen, Inc. BiotechnologyHealth Technology GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA. | Health Technology |
Grifols Innovation & New Technologies Ltd.
Grifols Innovation & New Technologies Ltd. BiotechnologyHealth Technology Grifols Innovation & New Technologies Ltd. provides research and experimental development services in biotechnology sector. The company was founded on December 21, 2015 and is headquartered in Dublin, Ireland. | Health Technology |
- Bolsa de valores
- Insiders
- David Ian Bell
- Experiencia